El esquema teraputico es escalonado: inicia, por lo general, con 2,5 mg por semana y puede avanzar hasta 15 mg, conforme a la respuesta metablica y la tolerancia del paciente
While it is believed that semaglutide leads to gastrointestinal disorders less than 5% of the time, transient, mild-to-moderate bouts of the following issues are commonplace among GLP-1 drugs: Nausea : 44% Vomiting: 25% Diarrhea: 32% Constipation: 23% Abdominal pain: 10% Fatigue, Dizziness, Headache Clinical data does not support the idea that semaglutide directly causes dizziness, headaches, or significant fatigue
they just do it in slightly different ways
Furthermore, data from Holst et al
Active in the telehealth GLP-1 supply chain